1. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients
- Author
-
Marchetti, Claudia, Palaia, I., De Felice, F., Musella, A., Donfracesco, C., Vertechy, L., Romito, A., Piacenti, I., Musio, D., Muzii, L., Tombolini, V., Benedetti Panici, P., Marchetti C. (ORCID:0000-0001-7098-8956), Marchetti, Claudia, Palaia, I., De Felice, F., Musella, A., Donfracesco, C., Vertechy, L., Romito, A., Piacenti, I., Musio, D., Muzii, L., Tombolini, V., Benedetti Panici, P., and Marchetti C. (ORCID:0000-0001-7098-8956)
- Abstract
For many decades, ovarian cancer (OC) has been one of the most common gynecological cancer. Despite advances in OC diagnosis and treatment, the risk of recurrence is ever present and approximately 85% of patients will experience relapse. Recurrent OC after first-line therapy is almost always incurable. Multiple novel therapies, including tyrosine-kinases inhibitors (TKI), have shown promising results, but their role needs to be clarified. In this review we describe the rationale and the clinical evidence regarding the use of TKI for the treatment of recurrent platinum-resistant OC patients.
- Published
- 2016